Search

Single-cell transcriptomics has emerged as a powerful tool for understanding how different cells contribute to disease progression by identifying cell types that change across diseases or conditions. However, detecting changing cell types is challenging due to individual-to-individual and cohort-to-cohort variability and naive approaches based on current computational tools lead to false positive findings. To address this, we propose a computational tool,scDist, based on a mixed-effects model that provides a statistically rigorous and computationally efficient approach for detecting transcriptomic differences. By accurately recapitulating known immune cell relationships and mitigating false positives induced by individual and cohort variation, we demonstrate thatscDistoutperforms current methods in both simulated and real datasets, even with limited sample sizes. Through the analysis of COVID-19 and immunotherapy datasets,scDistuncovers transcriptomic perturbations in dendritic cells, plasmacytoid dendritic cells, and FCER1G+NK cells, that provide new insights into disease mechanisms and treatment responses. As single-cell datasets continue to expand, our faster and statistically rigorous method offers a robust and versatile tool for a wide range of research and clinical applications, enabling the investigation of cellular perturbations with implications for human health and disease.

Although antibodies targeting specific tumor-expressed antigens are the standard of care for some cancers, the identification of cancer-specific targets amenable to antibody binding has remained a bottleneck in development of new therapeutics. To overcome this challenge, we developed a high-throughput platform that allows for the unbiased, simultaneous discovery of antibodies and targets based on phenotypic binding profiles. Applying this platform to ovarian cancer, we identified a wide diversity of cancer targets including receptor tyrosine kinases, adhesion and migration proteins, proteases and proteins regulating angiogenesis in a single round of screening using genomics, flow cytometry, and mass spectrometry. In particular, we identified BCAM as a promising candidate for targeted therapy in high-grade serous ovarian cancers. More generally, this approach provides a rapid and flexible framework to identify cancer targets and antibodies.

Unsupervised clustering of single-cell RNA-sequencing data enables the identification and discovery of distinct cell populations. However, the most widely used clustering algorithms are heuristic and do not formally account for statistical uncertainty. Many popular pipelines use clustering stability methods to assess the algorithms’ output and decide on the number of clusters. However, we find that by not addressing known sources of variability in a statistically rigorous manner, these analyses lead to overconfidence in the discovery of novel cell-types. We extend a previous method for Gaussian data, Significance of Hierarchical Clustering (SHC), to propose a model-based hypothesis testing approach that incorporates significance analysis into the clustering algorithm and permits statistical evaluation of clusters as distinct cell populations. We also adapt this approach to permit statistical assessment on the clusters reported by any algorithm. We benchmarked our approach on real-world datasets against popular clustering workflows, demonstrating improved performance. To show its practical utility, we applied it to the Human Lung Cell Atlas and an atlas of the mouse cerebellar cortex. We identified several cases of over-clustering, leading to false discoveries, as well as under-clustering, resulting in the failure to identify new subpopulations that our method was able to detect.

Spatial transcriptomics enables spatially resolved gene expression measurements at near single-cell resolution. The detection of genes that are differentially expressed across tissue context for cell types of interest is an essential challenge for dissecting pathological mechanisms. However, changes in cell type composition across space and measurement contamination from other cell types introduce complex statistical challenges. Here, we introduce a statistical method, Generalized Linear Admixture Models for Differential Expression (GLAMDE), that estimates cell type-specific patterns of differential gene expression while accounting for localization of other cell types. By modeling spatial transcriptomics gene expression as an additive mixture, across cell types, of generalized log-linear functions, we provide a unified framework for identifying gene expression changes for a wide-range of relevant contexts: changes due to pathology, anatomical regions, physical proximity to specific cell types, and cellular microenvironment. Our approach enables statistical inference across multiple samples and replicates. We demonstrate, through simulations and validation experiments on Slide-seq and MERFISH data, that our approach accurately identifies cell type-specific differential gene expression with valid uncertainty quantification. Lastly, we apply GLAMDE to characterize spatially-localized tissue changes in the context of disease. In an Alzheimer’s mouse model Slide-seq dataset, we identify plaque-dependent patterns of cellular immune activity. We also find a putative interaction between tumor cells and myeloid immune cells in a Slide-seq tumor dataset. GLAMDE is available within the spacexr R package. D.C. was supported by a Fannie and John Hertz Foundation Fellowship and an NSF Graduate Research Fellowship. This work was supported by an NIH Early Independence Award (DP5, 1DP5OD024583 to F.C.), the NHGRI (R01, R01HG010647 to F.C.), as well as the Burroughs Wellcome Fund, the Searle Scholars Award, and the Merkin Institute to F.C.. R.A.I. was supported by NIH grants R35GM131802 and R01HG005220.